We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Kenya's health ministry has begun distributing a more effective malaria treatment, artemisinin-based combination therapy (ACT), to public health centers in areas prone to epidemics.
South Korea and the United States have resolved a disagreement over Korea's new drug policy, one of the major hurdles in efforts to form a free trade pact.
Starting in August, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) will be changing the style of licenses issued for manufacturers and wholesale dealers, and some current license holders will also be required to hold a different type of license.
Chiesi Group announces the UK launch of Clenil Modulite (beclometasone dipropionate [BDP), a new CFC-free metered-dose inhaler (MDI) by their UK affiliate Trinity-Chiesi Pharmaceuticals.
Genentech, Inc., and Inotek Pharmaceuticals Corporation entered into an exclusive global collaboration to discover, develop, manufacture and commercialize inhibitors of poly (ADP-ribose) polymerase (PARP) for the potential treatment of cancer.
Switzerland-based Solvay Pharmaceuticals Marketing & Licensing AG, an affiliate of Solvay Pharmaceuticals (Brussels, Belgium) and Eisai Co. Ltd. concluded a license agreement on Solvay Pharmaceuticals' treatment for pancreatic exocrine insufficiency (SA-001) in Japan.
Astellas Pharma Europe, Ltd., the European affiliate of Astellas Pharma Inc. (Astellas), announced that Astellas instituted legal proceedings at the Juzgados de los Mercantil of Madrid against the generic pharmaceutical companies Ratiopharm España, S.A., Laboratorio Stada, S.L., Laboratorios Edigen, S.A., Merck Genéricos, S.L., Bexal Famacéutica, S.A., Sandoz Farmacéutica, S.A., and Teva Genéricos España, S.L., who have launched or are expected to launch modified-release hard capsules with the active ingredient tamsulosin hydrochloride on the Spanish market.